<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912869</url>
  </required_header>
  <id_info>
    <org_study_id>BO42452</org_study_id>
    <secondary_id>2020-004840-27</secondary_id>
    <nct_id>NCT04912869</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).</brief_title>
  <acronym>CROSSWALK-a</acronym>
  <official_title>A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain&#xD;
      crisis (also known as a VOE) that requires hospitalisation in adult and adolescent&#xD;
      participants with SCD. The primary objective of this study is safety and will additionally&#xD;
      evaluate pharmacokinetics (how crovalimab is processed by your body), pharmacodynamics (how&#xD;
      your body reacts to crovalimab) and the preliminary efficacy of crovalimab compared with&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">September 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Infusion-Related Reactions and Hypersensitivity</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of the primary acute uncomplicated VOE from Baseline</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cumulative opioid dose from Baseline</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discontinuation of all parenteral opioids from baseline</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to readiness for hospital discharge from baseline</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge from baseline</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a confirmed decrease in pain score of at least 2 points from the maximal pre-dose pain score</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain score from the maximal pre-dose pain score to the score at hospital discharge</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who develop Acute Chest Syndrome (ACS)</measure>
    <time_frame>Baseline up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants requiring intensive care unit (ICU)/critical care admission for SCD-related complications</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants requiring blood transfusion for SCD-related complications</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission rate for a VOE or VOE-related event within 28 days of discharge of the primary VOE</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Crovalimab over time</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD biomarkers including complement activity (CH50) over time</measure>
    <time_frame>Baseline up to Day 84</time_frame>
    <description>Assessed by a Liposome Immunoassay (LIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time in free C5 concentration</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time in soluble complement 5b 9 (sC5b-9) concentration</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies to Crovalimab</measure>
    <time_frame>Baseline up to Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Crovalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single IV infusion of matching Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crovalimab</intervention_name>
    <description>Crovalimab will be administered as a single dose of 1000 mg IV (for participants with a body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with a body weight &gt;=100 kg).</description>
    <arm_group_label>Crovalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as a single IV infusion, with an equal volume and over the same duration as weight- based crovalimab</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight &gt;=40 kg.&#xD;
&#xD;
          -  Confirmed diagnosis of HbSS (SCD genotype of sickle cell anemia) or HbSβ0 (SCD&#xD;
             genotype of sickle cell beta zero thalassemia).&#xD;
&#xD;
          -  Vaccination against Neisseria meningitidis.&#xD;
&#xD;
          -  Vaccinations against H. influenzae type B and S. pneumoniae.&#xD;
&#xD;
          -  Participants vaccinated against SARS-CoV-2 are eligible, as long as it has been 3 days&#xD;
             or more after inoculation with the vaccine.&#xD;
&#xD;
          -  Diagnosis of an acute uncomplicated VOE, that requires admission to a hospital/acute&#xD;
             medical facility and treatment with parenteral opioid analgesics.&#xD;
&#xD;
          -  Adequate hepatic and renal function.&#xD;
&#xD;
          -  Hemoglobin &gt;=5 g/dL.&#xD;
&#xD;
          -  Platelet count &gt;=100,000/µL.&#xD;
&#xD;
          -  Participants receiving sickle cell therapies must be on a stable dose for &gt;=28 days.&#xD;
&#xD;
          -  For female participants of childbearing potential, an agreement to remain abstinent or&#xD;
             use contraception for 6 months after the dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than 10 VOEs within the last 12 months prior to presentation, that have required&#xD;
             a medical facility visit.&#xD;
&#xD;
          -  Pain related to the current VOE ongoing for &gt;48 hours.&#xD;
&#xD;
          -  Acute pain related to avascular necrosis, hepatic or splenic sequestration, or&#xD;
             priapism.&#xD;
&#xD;
          -  Pain atypical of an acute uncomplicated VOE.&#xD;
&#xD;
          -  Evidence of or suspicion of ACS.&#xD;
&#xD;
          -  Evidence or high suspicion of a severe systemic infection.&#xD;
&#xD;
          -  Major surgery and/or hospitalization for any reason within 30 days.&#xD;
&#xD;
          -  History of Neisseria meningitidis infection within 6 months prior.&#xD;
&#xD;
          -  Known HIV infection with a documented CD4 count &lt;200 cells/µL.&#xD;
&#xD;
          -  Transfusion or receipt of blood products within 3 months or current participation in a&#xD;
             chronic transfusion protocol.&#xD;
&#xD;
          -  Immunized with a live attenuated vaccine within 30 days.&#xD;
&#xD;
          -  History of hematopoietic stem cell transplant.&#xD;
&#xD;
          -  Known or suspected hereditary complement deficiency.&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             6 months after the study drug administration.&#xD;
&#xD;
          -  Participation in another interventional treatment study with an investigational agent&#xD;
             or use of any experimental therapy within the prior 28 days or within five half-lives&#xD;
             of that investigational product, whichever was greater.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO42452 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Verona-Policlinico G.B. Rossi; Medicina Interna</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón; Oncología y Hematología Pediátricas y del Adolescente</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Hematologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaso-occlusive episodes</keyword>
  <keyword>Pain crisis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

